222 related articles for article (PubMed ID: 36609397)
1. Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Sherman MA; Kim H; Banschbach K; Brown A; Gewanter HL; Lang B; Perron M; Robinson AB; Spitznagle J; Stingl C; Syverson G; Tory HO; Spencer CH; Tarvin SE
Pediatr Rheumatol Online J; 2023 Jan; 21(1):3. PubMed ID: 36609397
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
3. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.
Hinze CH; Speth F; Oommen PT; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):38. PubMed ID: 29925381
[TBL] [Abstract][Full Text] [Related]
4. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
5. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
[TBL] [Abstract][Full Text] [Related]
7. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
[TBL] [Abstract][Full Text] [Related]
8. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.
Stringer E; Bohnsack J; Bowyer SL; Griffin TA; Huber AM; Lang B; Lindsley CB; Ota S; Pilkington C; Reed AM; Scuccimarri R; Feldman BM
J Rheumatol; 2010 Sep; 37(9):1953-61. PubMed ID: 20595275
[TBL] [Abstract][Full Text] [Related]
9. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
Orandi AB; Baszis KW; Dharnidharka VR; Huber AM; Hoeltzel MF;
Pediatr Rheumatol Online J; 2017 Sep; 15(1):71. PubMed ID: 28934971
[TBL] [Abstract][Full Text] [Related]
10. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis.
Angeles-Han ST; Lo MS; Henderson LA; Lerman MA; Abramson L; Cooper AM; Parsa MF; Zemel LS; Ronis T; Beukelman T; Cox E; Sen HN; Holland GN; Brunner HI; Lasky A; Rabinovich CE;
Arthritis Care Res (Hoboken); 2019 Apr; 71(4):482-491. PubMed ID: 29806733
[TBL] [Abstract][Full Text] [Related]
11. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.
Kim S; Kahn P; Robinson AB; Lang B; Shulman A; Oberle EJ; Schikler K; Curran ML; Barillas-Arias L; Spencer CH; Rider LG; Huber AM
Pediatr Rheumatol Online J; 2017 Jan; 15(1):1. PubMed ID: 28077146
[TBL] [Abstract][Full Text] [Related]
12. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
Huber AM; Kim S; Reed AM; Carrasco R; Feldman BM; Hong SD; Kahn P; Rahimi H; Robinson AB; Vehe RK; Weiss JE; Spencer C;
J Rheumatol; 2017 Jan; 44(1):110-116. PubMed ID: 27803135
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
14. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.
Hinze CH; Oommen PT; Dressler F; Urban A; Weller-Heinemann F; Speth F; Lainka E; Brunner J; Fesq H; Foell D; Müller-Felber W; Neudorf U; Rietschel C; Schwarz T; Schara U; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):40. PubMed ID: 29940960
[TBL] [Abstract][Full Text] [Related]
15. [Juvenile dermatomyositis-what's new?].
Hinze C
Z Rheumatol; 2019 Sep; 78(7):627-635. PubMed ID: 31087132
[TBL] [Abstract][Full Text] [Related]
16. Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.
Sener S; Cam V; Ozen S; Batu ED
Clin Rheumatol; 2024 Feb; 43(2):591-602. PubMed ID: 37582998
[TBL] [Abstract][Full Text] [Related]
17. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
18. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
Horton DB; Onel KB; Beukelman T; Ringold S
J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.
Neely J; Ardalan K; Huber A; Kim S;
Pediatr Rheumatol Online J; 2022 Jul; 20(1):50. PubMed ID: 35854378
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
